Programas de Trabalho e outras iniciativas A Saúde no ...•Topic 2: Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences

Programas de Trabalho e outras iniciativas A Saúde no Horizonte 2020

Patrícia Calado

Horizonte 2020 - Financiamento para empresas na área da Saúde 12 Novembro 2015

Entrar em pânico

Gabinete de Promoção dos Programa Quadro ID&I

Depois desta apresentação tem duas opções:

Preparar-se para ser

competitivo

eHealth

Proven Ideas

Horizon 2020

eHealth

Health

ICT & Ageing

Horizon 2020

New Knowledge

An

timicro

bial R

esistan

ce

Joint Programming Initiatives

Public Health Programme

Structural Funds EIB ESF CEF

Deployment support Evidence and innovation guidelines

Research Innovation Deployment

New solutions

Ambient Assisted

Living (AAL2)

EIP Active and Healthy Ageing

Biotechnology Nanotechnology ICT

Ne

uro

de

gen

erative

D

isease

s

INVESTIGAÇÃO E INOVAÇÃO EM SAÚDE NA EUROPA


A SAÚDE NO H2020

Saúde

Saúde

Saúde

Saúde Saúde Saúde

Saúde

Saúde

Saúde


A SAÚDE NO H2020

Saúde

Saúde Saúde


Saúde

OPORTUNIDADES DE FINANCIAMENTO DESAFIO SOCIETAL 1


Orçamento (2014-2020): EUR 7.257 M

3 Treating and managing disease

1 Understanding health, wellbeing and disease

2 Preventing disease

4 Active ageing and self-management of health

5 Methods and data

6 Health care provision and integrated care

DS1 – SAÚDE, ALTERAÇÕES DEMOGRÁFICAS E BEM ESTAR

Better health for all


TÓPICOS DA SAÚDE - CARACTERÍSTICAS

• Tópicos mais abertos

• Foco na inovação e no impacto

• Ênfase nos consumidores finais

• Mais estudos clínicos e proximidade do mercado

• Grande investimento nas ferramentas de ICT

• Questões transversais (SSH, gender aspects)

• Sinergias com outros financiamentos (fundos estruturais, AAL, EDCTP, EU Health Programme, etc).

• Forte envolvimento das PMEs e das entidades dos sistemas de saúde


• Orçamento total: ~934 M€

• Personalised Medicine (PM): ⁻ 21 tópicos ⁻ 608,76 M€

• Co-ordination Activities (HCO): ⁻ 15 tópicos ⁻ 49,5 M€

• SME Instrument: ⁻ 2 tópicos ⁻ 110,5 M€

• Other actions: 12 tópicos

PROGRAMA DE TRABALHOS DS1 2016-2017


HIGHLIGHTS PROGRAMA DE TRABALHOS DS1 2016-2017

Strategic orientation - “promoting healthy ageing and personalised healthcare”

• Personalised medicine

• Active and healthy ageing

• Human bio-monitoring

• e/mHealth (ICT)

• Infectious diseases (incl. vaccines)

• Maternal and child health


CALL PM: Understanding health, well-being and disease

M€

Projecto

M€

Total2016 2017

SC1-PM-01-2016: Multi omics for personalised therapies addressing

diseases of the immune systemRIA RTD 12-15 30 13-04-16

SC1-PM-02-2017: New concepts in patient stratification RIA RTD 4-6 40

04-10-16

(1st phase)

11-04-17

(2nd phase)

SC1-PM-03–2017: Diagnostic characterisation of rare diseases RIA RTD 15 15 11-04-17

SC1-PM-04–2016: Networking and optimising the use of population and

patient cohorts at EU levelRIA RTD 8-10 30 13-04-16

115 15%TOTAL

1.1 Understanding health, well-being and disease

TOPIC

TYPE OF

ACTIONDG

BUDGET DEADLINE


CALL PM: Preventing disease

M€

Projecto

M€

Total2016 2017

SC1-PM-05–2016: The European Human Biomonitoring InitiativeCOFUND

(EJP)RTD 50 50 13-04-16

SC1-PM-06–2016: Vaccine development for malaria and/or neglected

infectious diseases

a) Larger platforms proposals 15-20

b) Smaller proposals 3-5

SC1-PM-07–2017: Promoting mental healt and well-being in the young RIA RTD 2-4 20

04-10-16

(1st phase)

11-04-17

(2nd phase)

110 14%

RIA RTD 40 13-04-16

1.2 Preventing disease

TOPIC

TOTAL

TYPE OF

ACTIONDG

BUDGET DEADLINE


CALL PM: Treating and managing diseases

M€

Projecto

M€

Total2016 2017

SC1-PM-08–2017: New therapies for rare diseases RIA RTD 4-6 60

04-10-16

(1st phase)

11-04-17

(2nd phase)

SC1-PM-09–2016: New therapies for chronic diseases RIA RTD 4-6 60 13-04-16

SC1-PM-10–2017: Comparing the effectiveness of existing healthcare

interventions in the adult populationRIA RTD 4-6 40

04-10-16

(1st phase)

11-04-17

(2nd phase)

SC1-PM-11–2016-2017: Clinical research on regenerative medicine RIA RTD 4-6 30+30 13-04-16 11-04-17

160 21%

1.3 Treating and managing diseases

TOPIC

TOTAL

TYPE OF

ACTIONDG

BUDGET DEADLINE


CALL PM: Active ageing and self-management of health

M€

Projecto

M€

Total2016 2017

SC1-PM-12–2016: PCP - eHealth innovation in empowering the patient COFUND

(PCP)CNECT 3 18 16-02-16

SC1-PM-13–2016: PPI for deployment and scaling up of ICT solutions for

active and healthy ageing

COFUND

(PPI)CNECT 2-5 10,5 16-02-16

SC1-PM-14–2016: EU-Japan cooperation on Novel ICT Robotics based

solutions for active and healthy ageing at home or in care facilitiesRIA CNECT 1-2 5 19-01-16

SC1-PM-15-2017: Personalised coaching for well-being and care of

people as they ageRIA CNECT 3-4 25 31-01-17

58,5 8%

1.4 Active ageing and self-management of health

TOPIC

TOTAL

TYPE OF

ACTIONDG

BUDGET DEADLINE


CALL PM: Methods and data

M€

Projecto

M€

Total2016 2017

SC1-PM-16–2017: In-silico trials for developing and assessing biomedical

productsRIA CNECT 4-6 19 14-03-17

SC1-PM-17–2017: Personalised computer models and in-silico systems

for well-beingRIA CNECT 4-6 19 14-03-17

SC1-PM-18–2016: Big Data supporting Public Health policies RIA CNECT 3-5 10 16-02-16

SC1-PM-19–2017: PPI for uptake of standards for the exchange of

digitalised healthcare records

COFUND

(PPI)CNECT 3-4 8,26 14-03-17

SC1-PM-20-2017: Development of new methods and measures for

improved economic evaluation and efficiency measures in the health

sector

RIA RTD tbd 9 11-04-17

65,26 8%

1.5 Methods and data

TOPIC

TOTAL

TYPE OF

ACTIONDG

BUDGET DEADLINE


CALL PM: Health care provision and integrated care

M€

Projecto

M€

Total2016 2017

SC1-PM-21-2016: Implementation research for scaling-up of evidence

based innovations and good practice in Europe and low- and middle-

income countries

RIA RTD 4-6 40 13-04-16

40 5%

1.6 Health care provision and integrated care

TOPIC

TOTAL

TYPE OF

ACTIONDG

BUDGET DEADLINE


CALL: OTHER COORDINATION ACTIONS (I)

M€

Projecto

M€

Total2016 2017

SC1-HCO-01-2016: Valorisation of FP7 Health and H2020 SC1 research results CSA RTD 1-2 2 13-04-16

SC1-HCO-02-2016: Standardisation of pre-analytical and analytical procedures for in

vitro diagnostics in personalised medicineCSA RTD 2 2 13-04-16

SC1-HCO-03–2017: Implementing the Strategic Research Agenda on Personalised

Medicine

ERA-NET

CofundRTD 5 5 11-04-17

SC1-HCO-04–2016: Towards globalisation of the Joint Programming Initiative on

Antimicrobial resistanceCSA RTD 1-2 2 13-04-16

SC1-HCO-05–2016: Coordinating personalised medicine research CSA RTD 02 2 13-04-16

SC1-HCO-06–2016: Towards an ERA-NET for building sustainable and resilient health

system modelsCSA RTD 1-2 2 13-04-16

SC1-HCO-07–2017: Global Alliance for Chronic Diseases (GACD) RIA RTD tbd 24 11-04-17

SC1-HCO-08–2017: Actions to bridge the divide in European health research and

innovationCSA RTD 1 1 11-04-17

DEADLINEBudgetTYPE OF

ACTIONDG

Topic

Other Coordination Actions


CALL: OTHER COORDINATION ACTIONS (II)

Projecto Total 2016 2017

SC1-HCO-10–2016: Support for Europe’s leading Health ICT SMEs CSA CNECT 3 3 16-02-16

SC1-HCO-11–2016: Coordinated Action to support the recognition of Silver Economy

opportunities arising from demographic changeCSA CNECT 1 1 16-02-16

SC1-HCO-12–2016: Digital health literacy CSA CNECT 2 2 16-02-16

SC1-HCO-13–2016: Healthcare workforce IT skills CSA CNECT 0,5 0,5 16-02-16

SC1-HCO-14–2016: EU-US interoperability roadmap CSA CNECT 1 1 16-02-16

SC1-HCO-15-2016: EU eHealth Interoperability conformity assessment CSA CNECT 1 1 16-02-16

SC1-HCO-16-2016: Standardisation needs in the field of ICT for Active and Healthy

AgeingCSA CNECT 1 1 16-02-16

49,5TOTAL 6%

Other Coordination ActionsTYPE OF

ACTIONDG

Budget DEADLINE

Topic


CALL: OTHER ACTIONS

2016 2017 2016 2017

HOA 2 - InnovFin Infectious Diseases (InnovFin ID) Pilot Financial Instrument 50 50 Q1 Q1

HOA 8 - Horizon Prize on reducing maternal and new-born morbidity

and mortality - the Birth Day PrizeInducement Prize - Q21

Other Actions

TYPE OF ACTION

Budget M€ DEADLINE

TOPIC


CALL: SME INSTRUMENT

Continuously open call H2020-SMEInst-2016-2017, Horizon 2020 Work Programme Part – Innovation in SMEs

SME Instrument

TopicM€

Projecto2016 2017 Fase 1 Fase 2

SMEInst-05-2016-2017: Supporting innovative SMEs in the healthcare

biotechnology sector35 45

24-02-16 03-02-1603-05-16 14-04-1607-09-16 15-06-1609-11-16 13-10-16

- -15-02-17 18-01-1703-05-17 06-04-1706-09-17 01-06-1708-11-17 18-10-17

b) Clinical research for the validation of biomarkers and/or diagnostic medical devicesFase 2:

1-5M€0 10 - 15-02-17

24-02-16 03-02-1603-05-16 14-04-1607-09-16 15-06-1609-11-16 13-10-16

- -15-02-17 18-01-1703-05-17 06-04-1706-09-17 01-06-1708-11-17 18-10-17

53 57,5

CNECTSMESMEInst-06-2016-2017: Accelerating market introduction of ICT solutions for

Health, Well-Being and Ageing Well

Fase 1:

50.000 €;

Fase 2:

1-5M€

35 35

18 12,5

Fase 1:

50.000 €;

Fase 2:

1-5M€

a) Cell technologies in medical applications SME RTD

TYPE OF

ACTIONDG

Budget DEADLINE

TOTAL


INICIATIVAS ESTRATÉGICAS SAÚDE


Elisabete Pires [email protected]

Ricardo Pereira [email protected]


mailto:[email protected]

mailto:[email protected]

1 A 30% better success rate in clinical trials of priority medicines identified by the WHO;

2 Clinical proof of concept in immunological, respiratory,

neurological and neurodegenerative diseases in just five years;

3 New and approved diagnostic markers for four of these

diseases and at least two new medicines which could either be new antibiotics or new therapies for Alzheimer’s disease.

• Iniciativa Tecnológica Conjunta entre a União Europeia e a EFPIA

• Objectivos do IMI2 com base na Strategic Research Agenda (SRA):

INICIATIVA DOS MEDICAMENTOS INOVADORES (IMI2)

ORÇAMENTO TOTAL IMI2 (2014-2024): 3.276 M€ (1.638 M€ H2020 + 1.425 M€ EFPIA (in kind) + 213 M€ indústrias das ciências da vida)


• Topic 1: Development of a quantitative system toxicology (QST) platform

• Topic 2: Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences

Topics under the IMI programme Big Data for Better Outcomes:

• Topic 3: Real World Outcomes Across the AD Spectrum (ROADS) to Better Care

• Topic 4: Development of an outcomes focused informatics platform to empower policy makers and clinicians to optimize care for patients with hematologic malignancies

IMI2 – 6TH CALL FOR PROPOSALS (RIA, 2-stage)


• Ebola and other filoviral haemorrhagic fevers (Ebola+) programme: future outbreaks

• Validation of translational imaging methods in drug safety assessment (TRISTAN)

• Identification of drugable targets modulating misfolded proteins in major neurodegenerative diseases

• Pathological neuron-glia interactions in neuropathic pain

• Dry age-related macular degeneration: development of novel clinical endpoints for clinical trials with a regulatory and patient access intention

• A comprehensive ‘paediatric preclinical POC platform’ to enable clinical molecule development for children with cancer

• Identification and validation of non-invasive markers across the spectrum of nonalcoholic fatty liver disease (NAFLD)

Topics under the Big Data for Better Outcomes programme

• Coordination and support action (CSA) for the big data for better outcomes programme

• Increase access and use of high quality data to improve clinical outcomes in heart failure (HF), atrial fibrillation (AF), and acute coronary syndrome (ACS) patients

IMI2 – 7TH AND 8TH CALL FOR PROPOSALS


NCPs Saúde:


OPORTUNIDADES DE FINANCIAMENTO DESAFIO SOCIETAL 2


5 grandes atividades no Programa Específico do DS2

Agricultura e silvicultura

Sector Agro-

alimentar

Aquicultura e pescas

Bioindústrias e

bioeconomia

Investigação marinha e marítima

http://ec.europa.eu/programmes/horizon2020/en/h2020-section/food-security-sustainable-agriculture-and-forestry-marine-maritime-and-inland-water


























‘Sustainable Food Security’ call (SFS) 2016 2017

SAFE AND HEALTHY DIETS AND SUSTAINABLE CONSUMPTION

SFS-37: The impact of consumer practices in food safety: risks and mitigation strategies (RIA, 9,5M€)

X

SFS-38: Impulsivity and compulsivity and the link to nutrition, lifestyle and the socio-economic environment (RIA, 12M€ )

X

SFS-39: How to tackle the childhood obesity epidemic (RIA, 10M€)

X

SFS-40: Sweeteners and sweetness enhancers (RIA, 9M€)

X

BLUE GROWTH (BG)

17 Fev2016 | 14 Fev 2017 two-stage topics


Healthy oceans and seas for healthy people 2016 2017

BG-6: Interaction between humans, oceans and seas: a strategic approach towards healthcare and wellbeing (CSA, 2M€)

X

BG-8: Innovative sustainable solutions for improving the safety and dietary properties of seafood (IA, 7M€)

X

→ O objetivo é explorar a interação entre os oceanos e a saúde humana

PILLAR 2: Healthy oceans and seas for healthy people

14 Fev2017 One-stage topics


NCPs Bioeconomia:


OPORTUNIDADES DE FINANCIAMENTO NMBP


1 Materiais avançados e nanotecnologia para produtos de elevado valor acrescentado e indústria de processos

2 Materiais Avançados e Nanotecnologias para os Cuidados de Saúde

3 Materiais Avançados e Nanotecnologias para a Energia

4 Eco-design e novos modelos de negócio sustentáveis

6 Modelação para o desenvolvimento de nanotecnologias e materiais avançados

Avaliação e Gestão do risco das nanotecnologias, materiais avançados e biotecnologias

7

Áre

as T

em

átic

as 2

01

6/2

01

7

Governância inovadora e responsável de tecnologias facilitadoras novas e convergentes

8

Call for Nanotechnologies, Advanced materials, Biotechnology and Production

5 Biotecnologia


Tópico Ação Cont. EC/proj

NMBP-13-2017: Cross-cutting KETs for diagnostics at the point-of-care RIA 3 – 5 M€

NMBP-16-2017: Mobilising the European nano-biomedical ecosystem CSA 1-2 M€


NMBP-12-2017: Development of a reliable methodology for better risk management of engineered biomaterials in Advanced Therapy Medicinal Products and/or Medical Devices

RIA 5 – 8 M€

NMBP-14-2017: Regulatory Science Framework for assessment of risk benefit ratio of Nanomedicines and Biomaterials

RIA 5 – 8 M€

Apenas 1 projeto financiado

NMBP-15-2017: Nanotechnologies for imaging cellular transplants and regenerative processes in vivo

RIA 5 – 7 M€


NMBP-09-2016: Biomaterials for diagnosis and treatment of demyelination disorders of the Central Nervous System

RIA 5 – 8 M€

NMBP-10-2016: Nanoformulation of biologicals RIA 5 – 6 M€

Nanotecnologia e materiais avançados para Cuidados de Saúde mais eficazes


Biotecnologia

Tópico TRL Ação Contr. EC/proj

BIOTEC-03-2016: Microbial chassis platforms with optimized metabolic pathways for industrial innovations through systems biology SMEs encouraged

3 5 RIA 5 – 7 M€

BIOTEC-04-2016: KET Biotechnology foresight identifying gaps and high-value opportunities for the EU industry

CSA 350 – 500 K€ Apenas 1 projeto

financiado

Desenvolvimento de produtos e processos industriais competitivos, sustentáveis, seguros e inovadores;

Funciona como motor de inovação em vários setores europeus, como a agricultura, a silvicultura, a alimentação, a energia, os produtos químicos e a saúde, assim como a bioeconomia.

RIA: 8 Dez 2015 | 24 Maio 2016 CSA: 21 Jan 2017


NCPs NMBP:


Orientações para a preparação de uma

proposta em colaboração

COMO COMEÇAR?

• Ideia clara para um projeto

• Consistente com o tópico do programa de trabalhos

• Inovadora e com potencial de exploração

• Para além do estado-da-arte

• Dimensão Europeia!


IDENTIFICAR TÓPICOS DE INTERESSE

Pesquisa por keywords….

…ou por texto livre

Procurar no Participant Portal….


…ou estudar o Programa de Trabalhos!

IDENTIFICAR TÓPICOS DE INTERESSE


Parte A - Informação Administrativa: apenas formulários online!...incluindo abstract

Parte B - Informação Técnica: upload de PDF numa determinada estrutura

http://ec.europa.eu/research/participants/data/ref/h2020/call_ptef/pt/2016-2017/h2020-call-pt-ria-ia-2016-17_en.pdf

PREPARAÇÃO DA PROPOSTA


















• Preenchimento online

• Informação geral título, duração, palavras-chave, sumário

• Dados administrativos da organização parceira

• Orçamento global da proposta e de cada organização parceira

PARTE A – INFORMAÇÃO ADMINISTRATIVA


1. Excellence 1.1 Objectives 1.2 Relation to the work programme 1.3 Concept and approach 1.4 Ambition 2. Impact 2.1 Expected impacts 2.2 Measures to maximise impact a) Dissemination and exploitation of results b) Communication activities 3. Implementation 3.1 Work plan — Work packages, deliverables and milestones 3.2Management structure and procedures 3.3 Consortium as a whole 3.4 Resources to be committed 4. Members of the consortium 4.1 Participants (applicants) 4.2 Third parties involved in the project (including use of third party resources) 5. Ethics and Security 5.1Ethics 5.2 Security

PARTE B – INFORMAÇÃO TÉCNICA

Max 70 páginas!


CRITÉRIOS DE AVALIAÇÃO

Excellence Impact Quality and efficiency of

the implementation

Detalhes da avaliação dependentes do tipo de acção

5 5 5


PROPOSTAS H2020 – ABORDAGEM INTEGRADA

soluções para o problema

inovadora

viável nas metas propostas

competências e complementaridade no

consórcio

dimensão Europeia

bem orçamentada

estrutura de gestão adequada à dimensão

do consórcio e complexidade da proposta

Painel de Avaliação


FERRAMENTAS DE PROCURA DE PARCEIROS EU E PT


Proposta convincente

Consórcio sólido

Ideia

http://www.gppq.pt/h2020/contactos_ncp.php

GPPQ – Gabinete de Promoção do Programa-Quadro

www.gppq.pt/h2020/

Verifique o calendário das sessões de divulgação e workshops sobre escrita de propostas



http://www.gppq.pt/h2020/

Documents

Programas de Trabalho e outras iniciativas A Saúde no ...•Topic 2: Establishing impact of RSV infection, resultant disease and public health approach to reducing the consequences